Page last updated: 2024-11-05

troglitazone and Alzheimer Disease

troglitazone has been researched along with Alzheimer Disease in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Combs, CK1
Johnson, DE1
Karlo, JC1
Cannady, SB1
Landreth, GE1

Other Studies

1 other study available for troglitazone and Alzheimer Disease

ArticleYear
Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jan-15, Volume: 20, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-S

2000